Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

NCT03677557 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Primary Immunodeficiency Disease
Secondary Immunodeficiency

Interventions

DRUG: 16,5% Cutaquig

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]